Evidence map›Paper›PMID 25286283›Full record

ArticleJAMA pediatrics2014

Influence of age at virologic control on peripheral blood human immunodeficiency virus reservoir size and serostatus in perinatally infected adolescents.

Deborah Persaud, Kunjal Patel, Brad Karalius, Kaitlin Rainwater-Lovett, Carrie Ziemniak, Angela Ellis, Ya Hui Chen, Douglas Richman, George K Siberry, Russell B Van Dyke and 4 more

Erratum issued Registry-linked trialAbstract read
In one paragraph

Article in JAMA pediatrics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT01418014 (Adolescent Master Protocol), which is not on this map. Cited by 62 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01418014 completednot on this map

Adolescent Master Protocol

TypeobservationalSponsorHarvard School of Public Health (HSPH)Ran2007 to 2021Enrolled678ConditionsHIV/AIDS
3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Quantitative Human Immunodeficiency Virus (HIV)-1 Antibodies Correlate With Plasma HIV-1 RNA and Cell-associated DNA Levels in Children on Antiretroviral Therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019
    Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Research Toward a Cure for Perinatal HIV.Clinics in perinatology · 2024
    Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. The Contributions of Clinical Pharmacology to HIV Cure Research.Clinical pharmacology and therapeutics · 2021
    Review
  20. Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

14 authors.

Deborah PersaudDepartment of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Kunjal PatelDepartment of Epidemiology and the Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts.
Brad KaraliusDepartment of Epidemiology and the Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts.
Kaitlin Rainwater-LovettDepartment of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Carrie ZiemniakDepartment of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Angela EllisFrontier Science and Technology Research Foundation, Inc, Buffalo, New York.
Ya Hui ChenDepartment of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Douglas RichmanDepartment of Pathology, University of California, San Diego, La Jolla5Veterans Affairs San Diego Healthcare System, San Diego, California.
George K SiberryMaternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland.
Russell B Van DykeDepartment of Pediatrics, Tulane University School of Medicine, New Orleans, Louisiana.
Sandra BurchettDivision of Infectious Diseases, Boston Children's Hospital, Boston, Massachusetts.
George R SeageDepartment of Epidemiology and the Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts.
Katherine LuzuriagaProgram in Molecular Medicine, Department of Pediatrics, University of Massachusetts Medical School, Worcester10Center for Clinical and Translational Science, University of Massachusetts Medical School, Worcester.
Pediatric HIV/AIDS Cohort Study

Funding

PHACS - Data and Operations CenterU01HD052102 · NICHD · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI WILLIAMS, PAIGE L · 2005 to 2019
$242.7M
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) GroupU01AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI JACKSON, J BROOKS · 2006 to 2010
$109.7M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Sharon L. Hillier, JONATHAN KARN · 1994 to 2026
$50.0M
Colorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$48.0M
Using NK Cells to eliminate the latent HIV reservoirU19AI096113 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WOELK, CHRISTOPHER H · 2011 to 2015
$39.5M
Pediatric HIV/AIDS Cohort Study (PHACS): Understanding Maternal HIV Disease through Pregnancy and the Postpartum Period and its Role in Child Health OutcomesU01HD052104 · NICHD · TULANE UNIVERSITY OF LOUISIANA · PI VAN DYKE, RUSSELL B. · 2005 to 2019
$15.7M
Early Antiretroviral Therapy and HIV Remission in Perinatal InfectionR01HD080474 · NICHD · JOHNS HOPKINS UNIVERSITY · PI BRYSON, YVONNE J., LUZURIAGA, KATHERINE F · 2014 to 2018
$6.5M
HIV-1 chemoprophylaxis and archived drug resistance in infantsR01HD057784 · NICHD · JOHNS HOPKINS UNIVERSITY · PI PERSAUD, DEBORAH · 2007 to 2010
$2.3M
Novel Artemisinin Derivatives for Cytomegalovirus TherapyR01AI093701 · NIAID · JOHNS HOPKINS UNIVERSITY · PI BOGER, RAVIT · 2011 to 2015
$2.0M
Markers of Long-Term Suppression of HIV in Pre-adolescents treated from InfancyR21AI100656 · NIAID · JOHNS HOPKINS UNIVERSITY · PI PERSAUD, DEBORAH · 2013 to 2014
$605k
NCATS NIH HHS UL1 TR001082NIAID NIH HHS AI306214NIAID NIH HHS P30 AI036219NIAID NIH HHS P30 AI094189NIAID NIH HHS P30-AI094189NIAID NIH HHS R01 AI093701NIAID NIH HHS R21 AI100656NIAID NIH HHS R21AI100656NIAID NIH HHS U01 AI068632NIAID NIH HHS U01-AI-068632NIAID NIH HHS U19 AI096113NICHD NIH HHS 3 U01 HD052102-05S1NICHD NIH HHS 3 U01 HD052102-06S3NICHD NIH HHS 3U01 HD052104-06S1NICHD NIH HHS HD052102NICHD NIH HHS HD052104NICHD NIH HHS R01 HD057784NICHD NIH HHS R01HD080474NICHD NIH HHS U01 HD052102NICHD NIH HHS U01 HD052104
6 · The paper itself

Abstract

importanceCombination antiretroviral therapy initiated within several weeks of human immunodeficiency virus (HIV) infection in adults limits proviral reservoirs that preclude HIV cure. Biomarkers of restricted proviral reservoirs may aid in the monitoring of HIV remission or cure.

objectivesTo quantify peripheral blood proviral reservoir size in perinatally HIV-infected (PHIV+) adolescents and to identify correlates of limited proviral reservoirs. DESIGN, SETTING, AND

participantsA cross-sectional study including 144 PHIV+ youths (median age, 14.3 years) enrolled in the United States-based Pediatric HIV/AIDS Cohort Study and receiving durable (median duration, 10.2 years) combination antiretroviral therapy, stratified by age at virologic control. MAIN OUTCOMES AND MEASURES: The primary end point was peripheral blood mononuclear cell (PBMC) proviral load after virologic control at different ages. Correlations between proviral load and markers of active HIV production (ie, HIV-specific antibodies, 2-long terminal repeat circles) and markers of immune activation and inflammation were also assessed.

resultsProviral reservoir size was markedly reduced in the PHIV+ youth who achieved virologic control before 1 year of age (4.2 [interquartile range, 2.6-8.6] copies per 1 million PBMCs) compared with those who achieved virologic control at 1 to 5 years of age (19.4 [interquartile range, 5.5-99.8] copies per 1 million PBMCs) or after 5 years of age (70.7 [interquartile range, 23.2-209.4] copies per 1 million PBMCs; P < .001). A proviral burden of less than 10 copies per 1 million PBMCs in PHIV+ youth was measured in 11 (79%), 20 (40%), and 13 (18%) participants with virologic control before 1 year, at 1 to 5 years, and after 5 years of age, respectively (P < .001). Lower proviral load was associated with undetectable 2-long terminal repeat circles (P < .001) and HIV-negative or indeterminate serostatus (P < .001) but not with concentrations of soluble immune activation markers CD14 and CD163. CONCLUSIONS AND RELEVANCE: Early effective combination antiretroviral therapy with prolonged virologic suppression after perinatal HIV infection leads to negligible peripheral blood proviral reservoirs in adolescence and is associated with negative or indeterminate HIV serostatus. These findings highlight the long-term effect of early effective control of HIV replication on biomarkers of HIV persistence in perinatal infection and the utility of HIV serostatus as a biomarker for small proviral reservoir size, although not necessarily for cure.

Indexed as

ProvirusesViral LoadAdolescentAge FactorsAnti-Retroviral AgentsCD4 Lymphocyte CountChildChild, PreschoolCross-Sectional StudiesFemaleHIV InfectionsHumansInfantInfectious Disease Transmission, VerticalLeukocytes, MononuclearMaleAnti-Retroviral Agents

Identifiers

PMID25286283
PMCPMC4324476

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.